Rocket Lab remains rated sell due to overvaluation, execution risk, dilution, and heightened competition from SpaceX’s IPO. Neutron rocket delays to 2027 threaten RKLB’s core investment thesis, as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results